Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationIndividualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. 2016, 100 (5):683-7 Br J Ophthalmol
AbstractTo validate a mathematical algorithm that calculates risk of diabetic retinopathy progression in a diabetic population with UK staging (R0-3; M1) of diabetic retinopathy. To establish the utility of the algorithm to reduce screening frequency in this cohort, while maintaining safety standards.
The cohort of 9690 diabetic individuals in England, followed for 2 years. The algorithms calculated individual risk for development of preproliferative retinopathy (R2), active proliferative retinopathy (R3A) and diabetic maculopathy (M1) based on clinical data. Screening intervals were determined such that the increase in risk of developing certain stages of retinopathy between screenings was the same for all patients and identical to mean risk in fixed annual screening. Receiver operating characteristic curves were drawn and area under the curve calculated to estimate the prediction capability.
The algorithm predicts the occurrence of the given diabetic retinopathy stages with area under the curve =80% for patients with type II diabetes (CI 0.78 to 0.81). Of the cohort 64% is at less than 5% risk of progression to R2, R3A or M1 within 2 years. By applying a 2 year ceiling to the screening interval, patients with type II diabetes are screened on average every 20 months, which is a 40% reduction in frequency compared with annual screening.
The algorithm reliably identifies patients at high risk of developing advanced stages of diabetic retinopathy, including preproliferative R2, active proliferative R3A and maculopathy M1. Majority of patients have less than 5% risk of progression between stages within a year and a small high-risk group is identified. Screening visit frequency and presumably costs in a diabetic retinopathy screening system can be reduced by 40% by using a 2 year ceiling. Individualised risk assessment with 2 year ceiling on screening intervals may be a pragmatic next step in diabetic retinopathy screening in UK, in that safety is maximised and cost reduced by about 40%.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to The British journal of ophthalmology
- Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.
- Authors: Aspelund T, Thornórisdóttir O, Olafsdottir E, Gudmundsdottir A, Einarsdóttir AB, Mehlsen J, Einarsson S, Pálsson O, Einarsson G, Bek T, Stefánsson E
- Issue date: 2011 Oct
- A Diabetic Retinopathy Screening Tool for Low-Income Adults in Mexico.
- Authors: Mendoza-Herrera K, Quezada AD, Pedroza-Tobías A, Hernández-Alcaraz C, Fromow-Guerra J, Barquera S
- Issue date: 2017 Oct 12
- External validation of a risk assessment model to adjust the frequency of eye-screening visits in patients with diabetes mellitus.
- Authors: Soto-Pedre E, Pinies JA, Hernaez-Ortega MC
- Issue date: 2015 May-Jun
- Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England.
- Authors: Jones CD, Greenwood RH, Misra A, Bachmann MO
- Issue date: 2012 Mar
- Evaluation of Automated Teleretinal Screening Program for Diabetic Retinopathy.
- Authors: Walton OB 4th, Garoon RB, Weng CY, Gross J, Young AK, Camero KA, Jin H, Carvounis PE, Coffee RE, Chu YI
- Issue date: 2016 Feb